Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Nakamura

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 18, 2020
Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancerAkinori Sasaki, Yoshiaki Nakamura, Yosuke Togashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal CancerHideaki Bando, Yuichiro Tsukada, Koji Inamori, et al.
International Journal of Clinical Oncology|May 16, 2024
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesisHirotoshi Iihara, Masakazu Abe, Makoto Wada, et al.
Oncology and Therapy|July 24, 2020
Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone MetastasesShunji Takahashi, Seigo Kinuya, Norio Nonomura, et al.
International Journal of Clinical Oncology|November 12, 2024
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Saki Harashima, Rena Kaneko, et al.
International Journal of Clinical Oncology|November 21, 2024
Clinical benefits of adding olanzapine to 5-HT<sub>3</sub> receptor antagonist, NK<sub>1</sub> receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyMichiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, et al.
International Journal of Clinical Oncology|May 9, 2024
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023Masamitsu Kobayashi, Jun Kako, Arisa Iba, et al.
International Journal of Clinical Oncology|September 28, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyAyako Yokomizo, Kazuhisa Nakashima, Arisa Iba, et al.
International Journal of Clinical Oncology|September 11, 2024
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncologyToshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata, et al.
International Journal of Clinical Oncology|October 17, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 18, 2020
Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancerAkinori Sasaki, Yoshiaki Nakamura, Yosuke Togashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal CancerHideaki Bando, Yuichiro Tsukada, Koji Inamori, et al.
International Journal of Clinical Oncology|May 16, 2024
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesisHirotoshi Iihara, Masakazu Abe, Makoto Wada, et al.
Oncology and Therapy|July 24, 2020
Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone MetastasesShunji Takahashi, Seigo Kinuya, Norio Nonomura, et al.
International Journal of Clinical Oncology|November 12, 2024
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Saki Harashima, Rena Kaneko, et al.
International Journal of Clinical Oncology|November 21, 2024
Clinical benefits of adding olanzapine to 5-HT<sub>3</sub> receptor antagonist, NK<sub>1</sub> receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyMichiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, et al.
International Journal of Clinical Oncology|May 9, 2024
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023Masamitsu Kobayashi, Jun Kako, Arisa Iba, et al.
International Journal of Clinical Oncology|September 28, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyAyako Yokomizo, Kazuhisa Nakashima, Arisa Iba, et al.
International Journal of Clinical Oncology|September 11, 2024
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncologyToshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata, et al.
International Journal of Clinical Oncology|October 17, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, et al.
Pageof 17